ArticleActa parasitologica2025
Evaluating the Immunoprotective and Diagnostic Potential of Schistosoma mansoni Epitopes from Sm050890 and Sm141290 Proteins Identified Through Reverse Vaccinology.
Article in Acta parasitologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeSchistosomiasis remains a parasitic disease affecting millions of people worldwide, requiring interventions like vaccination. In previous work, our group used reverse vaccinology to identify two epitopes from the Schistosoma mansoni proteins, Sm050890 (44-58) and Sm141290 (225-239). This study evaluated the immune response profile and protection induced by peptides, as a mixture of immunogens, in murine vaccination trials. Additionally, the diagnostic potential of these peptides was assessed on immunoassays.
methodsMice were immunized with a formulation containing the mixture of the peptides, subsequently infected, and perfused for worm burden recovery and quantification. Liver and blood samples from animals were used to evaluate the effect of immunization on the formation of granulomas and specific anti-peptide antibodies (IgG). Additionally, cytokine measurement was performed in splenocyte cultures from immunized mice, and peripheral blood serum from individuals infected with S. mansoni was used to assess the recognition of the peptides by IgG antibodies.
resultsThe vaccine stimulated an increase in the production of IgG and IgG2c antibodies, associated with a significant reduction of 44 - 29% in worm burden. Although the vaccine did not reduce liver pathology, it enhanced the production of IFN-γ while decreasing IL-10 production by splenocytes. Furthermore, the peptides Sm050890 (44-58) and Sm141290 (225-239) were not recognized by IgG antibodies in the serum from infected individuals.
conclusionOverall, our data suggest that the peptides Sm050890 (44-58) and Sm141290 (225-239) are promising vaccine candidates against schistosomiasis and can be used to compose a multiepitope/chimeric vaccine in future studies.
Indexed as
Identifiers
39775981What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.